Skip to main content

Table 1 Patient Demographics

From: Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma

 

All (N = 58)

Group 1 (N = 13)

Group 2 (N = 35)

Group 3 (N = 10)

Median Weight (kg)

30.1

25.2

30.3

33.3

Range (Min, Max)

5, 85

6, 53

6, 85

5, 52

Median Age (yr)

7

7

7

7

Range (Min, Max)

3, 12

4, 12

3, 12

3, 13

Sex

 Female

22

7

11

2

 Male

36

6

23

7

Stage

 II

1

0

1

0

 III

36

7

21

6

 IV

18

5

10

3

 V

3

1

2

0

Immunophenotype

 B-cell (Naïve)

28

9

19

0

 B-cell (Relapsed)

14

2

6

6

 T-cell (Naïve)

7

1

6

0

 T-cell (Relapsed)

7

1

3

3

 Not Determined

2

0

1

1

Corticosteroid Use

 Prior prednisone

15

1

8

6

 Prednisone use after enrollment

25

7

15

3

 No prednisone use

18

5

11

1